3-chloro-N-((3S)-1-(1-(methylamino)-2,3-dihydro-1H-inden-5-yl)-2-oxopyrrolidin-3-yl)-1-(triisopropylsilyl)-1H-indole-6-sulfonamide | 1314254-32-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-chloro-N-((3S)-1-(1-(methylamino)-2,3-dihydro-1H-inden-5-yl)-2-oxopyrrolidin-3-yl)-1-(triisopropylsilyl)-1H-indole-6-sulfonamide
• CAS: 1314254-32-4
• 化学式: C₃₁H₄₃ClN₄O₃SSi
• 分子量: 615.312
• InChiKey: QKZLJJIRKALHIV-XIJSCUBXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.61
• 重原子数：
  41.0
• 可旋转键数：
  9.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  83.44
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  3-chloro-N-((3S)-1-(1-(methylamino)-2,3-dihydro-1H-inden-5-yl)-2-oxopyrrolidin-3-yl)-1-(triisopropylsilyl)-1H-indole-6-sulfonamide 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 生成 3-chloro-N-{(3S)-1-[1-(methylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl}-1H-indole-6-sulfonamide
  参考文献：
  名称：

  Structure and property based design of factor Xa inhibitors: Pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs

  摘要：

  The rational design, syntheses and evaluation of potent sulfonamidopyrrolidin-2-one-based factor Xa inhibitors incorporating aminoindane and phenylpyrrolidine P4 motifs are described. These series delivered highly potent anticoagulant compounds with excellent oral pharmacokinetic profiles; however, significant time dependant P450 inhibition was an issue for the aminoindane series, but this was not observed with the phenylpyrrolidine motif, which produced candidate quality molecules with potential for once-daily oral dosing in humans. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.131
• 作为产物：
  描述：

  在 吡啶 、 盐酸 、 甲醇 、 水 、 sodium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 生成 3-chloro-N-((3S)-1-(1-(methylamino)-2,3-dihydro-1H-inden-5-yl)-2-oxopyrrolidin-3-yl)-1-(triisopropylsilyl)-1H-indole-6-sulfonamide
  参考文献：
  名称：

  Structure and property based design of factor Xa inhibitors: Pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs

  摘要：

  The rational design, syntheses and evaluation of potent sulfonamidopyrrolidin-2-one-based factor Xa inhibitors incorporating aminoindane and phenylpyrrolidine P4 motifs are described. These series delivered highly potent anticoagulant compounds with excellent oral pharmacokinetic profiles; however, significant time dependant P450 inhibition was an issue for the aminoindane series, but this was not observed with the phenylpyrrolidine motif, which produced candidate quality molecules with potential for once-daily oral dosing in humans. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.131